In this regard, BC is pathologically classified as ERα/PR-positive, HER2-positive or as triple-negative breast cancer (TNBC), which lack the expression of these receptors and can themselves be considered a very heterogeneous group of cancers [12, 13]. This evidence concerns the gene ERBB2 and breast cancer.